Animal Models Core
Animal Models Core
批准号:
10470334
负责人:
DAVID A STOLTZ
金额:
$59.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-01 至 2025-07-31
关键词:
AddressAffectAirway DiseaseAnimal ModelAnimalsBiliary cirrhosisBiologicalBloodBronchoalveolar Lavage FluidCaringCell Culture TechniquesConsultationsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDiseaseDisease ProgressionEnsureExocrine pancreasFamily suidaeFerretsGallbladderGenesGenetic EngineeringGoalsHarvestHumanHuman ResourcesInfectionIntestinal ObstructionIntestinesKnowledgeLiverLungMale Genital OrgansMeasuresMicrobiologyModelingMolecularMonitorMorbidity - disease rateMouse StrainsMutationNeonatalOrganPancreasPancreatic DiseasesPathogenesisPathologyPatientsPreventionProductionProgram Research Project GrantsPulmonary Cystic FibrosisResearch PersonnelRespiratory Tract InfectionsSamplingSinusStructural defectSweat GlandsTimeVas deferens structureairway inflammationanimal carecystic fibrosis mousedisease-causing mutationexperiencehealth assessmentimprovedin vitro Modelmortalityprogramsreproductive tractsample collectionsmall moleculesuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CORE C – ANIMAL MODELS
PROJECT SUMMARY
Cystic fibrosis (CF) is a common autosomal recessive disease caused by mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR). CF affects multiple organs, including lungs,
pancreas, intestine, liver, sweat glands, gallbladder, and the male genital tract. Airway infection and
inflammation currently cause most of the morbidity and mortality. Although several therapies have improved the
lives of patients, current treatments are inadequate and CF remains a lethal disease. Our knowledge about the
pathogenesis of the disease, its progression, and the state of the neonatal lung is inadequate. These gaps in
our knowledge have hindered attempts to develop better treatments and preventions for CF lung disease. A
major impediment to addressing these issues had been limitations of animal models. Although mouse strains
carrying null and missense CFTR mutations have made enormous contributions, CF mice do not develop the
airway or pancreatic disease typically found in humans. We have generated CF ferrets and pigs that replicate
many of the key features of human CF disease including intestinal obstruction, exocrine pancreatic destruction,
micro-gallbladder, vas deferens abnormalities, focal biliary cirrhosis, congenital airway structural abnormalities,
and airway and sinus infection with time. The goals of the Animal Models Core will be: (1) To provide Program
investigators with non-CF and CF ferrets and pigs so that they can successfully complete their project aims. (2)
To build new genetically engineered CF ferret models that express CFTR in a regulated fashion. (3) To assist
projects in carrying out small molecule delivery, the harvesting of biologic samples from live animals (e.g.,
bronchoalveolar lavage fluid, blood, and microbiological samples), and the care and analysis of study animals.
(4) To assist projects in record keeping and coordinate animal usage among projects. The Animal Models Core
will function seamlessly through already established interactions with the Project Leaders, Pathology Core, In Vitro
Models and Cell Culture Core, and the Administrative Core. The success of the Animal Models Core is ensured
because of the commitment, experience, and expertise that the personnel bring to the Core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Climate Change and Lung Health Training Program
-
批准号:10556149
-
项目类别:
-
资助金额:$28.85万
-
财政年份:2023
-
负责人:DAVID A STOLTZ
-
依托单位:
Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health
-
批准号:10597111
-
项目类别:
-
资助金额:$62.95万
-
财政年份:2022
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10677590
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10024664
-
项目类别:
-
资助金额:$61.06万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Animal Models Core
-
批准号:10248526
-
项目类别:
-
资助金额:$60.83万
-
财政年份:2020
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:10155587
-
项目类别:
-
资助金额:$105.36万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:9289053
-
项目类别:
-
资助金额:$107.03万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
-
批准号:9918957
-
项目类别:
-
资助金额:$105.46万
-
财政年份:2017
-
负责人:DAVID A STOLTZ
-
依托单位:
Airway Goblet Cells: Friend or Foe?
-
批准号:8355114
-
项目类别:
-
资助金额:$226.5万
-
财政年份:2012
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:8110743
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2010
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:7919812
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2009
-
负责人:DAVID A STOLTZ
-
依托单位:
Project 1: Mucociliary Transport in Cystic Fibrosis Lung Disease
-
批准号:10470210
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Core A: Animals Models-Stoltz
-
批准号:10470206
-
项目类别:
-
资助金额:$71.22万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Origins of Cystic Fibrosis Airway Disease
-
批准号:10470203
-
项目类别:
-
资助金额:$229.33万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Porcine PPG Administration Core
-
批准号:10470205
-
项目类别:
-
资助金额:$6.23万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Origins of Cystic Fibrosis Airway Disease
-
批准号:10226930
-
项目类别:
-
资助金额:$229.38万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Core A: Animals Models-Stoltz
-
批准号:10226932
-
项目类别:
-
资助金额:$71.27万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Porcine PPG Administration Core
-
批准号:10226931
-
项目类别:
-
资助金额:$6.23万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Project 1: Mucociliary Transport in Cystic Fibrosis Lung Disease
-
批准号:10226937
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2008
-
负责人:DAVID A STOLTZ
-
依托单位:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
-
批准号:7994211
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2007
-
负责人:DAVID A STOLTZ
-
依托单位:
海外基金